Abacavir, Dolutegravir, and Lamivudine Uses, Dosage, Side Effects and Interactions
Triumeq
Triumeq was approved by the FDA in August 2014 as a tablet. No generic is listed as tablets.
Triumeq PD
Triumeq PD was approved by the FDA in March 2022 as a tablet. No generic is listed as tablets.
Abacavir, dolutegravir, and lamivudine is a three-drug combination used to treat HIV-1 infection in adults and in children aged at least 3 months who weigh at least 6 kg.
Quick links
Ask Anything About Abacavir, Dolutegravir, and LamivudineType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Abacavir, Dolutegravir, and Lamivudine in Short
- Drug classes Hepatitis B Nucleoside Analog Reverse Transcriptase Inhibitor; HIV Nucleoside Analog Reverse Transcriptase Inhibitor; HIV Integrase Strand Transfer Inhibitor How the FDA classifies it
What it treatsThis combination treats HIV-1 infection in adults and in pediatric patients aged at least 3 months and weighing at least 6 kg. It is sold as Triumeq and Triumeq PD. It is not recommended on its own if you have, or may have, resistance to a class of HIV drugs called integrase strand transfer inhibitors (INSTIs).
- How you get it Prescription only
- Comes asTablet (by mouth)Available strengths (abacavir/dolutegravir/lamivudine)
- 300 mg
- 600 mg/50 mg/300 mg
- The FDA’s strongest warningBoxed warning The FDA’s most serious alert. Read what it says
- Supplements and herbs56 interact 4 major, 43 moderate and 9 minor
- What pharmacies pay
- Triumeq (brand)$130.09 a tablet
- Generic launchsometime in 2028 Triumeq PD: sometime in 2028 Our estimate for the first generic of Triumeq
The Pharmacist’s Take
Triumeq is a complete HIV-1 treatment in one tablet, pairing dolutegravir, which keeps HIV from inserting itself into your cells, with abacavir and lamivudine, which block the enzyme HIV uses to copy itself; on the market for over a decade and not available generically, it is a well-established choice for people without the HLA-B*5701 gene. Most people tolerate it well; trouble sleeping, headache and tiredness are what they notice most. Its main boxed warning is a serious, sometimes fatal allergic reaction to abacavir, usually in the first 6 weeks, with fever, rash, vomiting, diarrhea, cough or feeling very unwell; stop it, get help right away, and never restart it.
Key Takeaways From the HelloPharmacist Team
- Take it once a day, with or without food, and avoid skipping doses, because missed doses give HIV a chance to become resistant.
- If it keeps you awake, taking it in the morning often helps, and trouble sleeping and headaches tend to ease over the first few weeks.
- Never stop it on your own if you have hepatitis B, because stopping can set off a severe flare that damages the liver.
- Never combine it with dofetilide, a heart rhythm medicine, and expect your prescriber to recheck your metformin dose, since dolutegravir can raise metformin levels.
FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about Abacavir, Dolutegravir, and Lamivudine.
Serious, sometimes fatal allergic reactions can happen with the abacavir in this medicine. They can affect several parts of the body at once. Your risk is higher if you carry the HLA-B*5701 gene, so you should be tested before you start.
If you may be having a reaction, stop the medicine right away and get medical help. Never restart it, or any abacavir-containing medicine, after a reaction. Symptoms can return more severely within hours.
This medicine also carries a risk for people with hepatitis B. You should be tested before starting. Lamivudine-resistant hepatitis B has been reported, and severe flare-ups of hepatitis B can occur if you stop this medicine. Your liver should be closely monitored if that happens.
Patient Information Guide for Abacavir, Dolutegravir, and Lamivudine
What It’s Used For
This three-drug combination treats HIV-1 infection.
- Triumeq and Triumeq PD treat HIV-1 infection in adults.
- They are also used in pediatric patients aged at least 3 months who weigh at least 6 kg.
- They are not recommended alone if integrase inhibitor resistance is present or suspected.
How It Works
Dolutegravir is an integrase strand transfer inhibitor (INSTI). Abacavir and lamivudine are nucleoside analogue reverse transcriptase inhibitors. Together they attack HIV-1 at more than one step.
Because the dolutegravir dose in this combination is fixed, it is not enough if integrase inhibitor resistance is present.
Drug Class
Drug Class
- Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor from dolutegravir
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor from abacavir
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor from lamivudine
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor from lamivudine
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class. Abacavir, Dolutegravir, and Lamivudine has three active ingredients, so each class says which one it comes from.
Drug Class
Established Pharmacologic Class (EPC)- Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor from dolutegravir
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor from abacavir
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor from lamivudine
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor from lamivudine
The main drug class the FDA gives it. It is the class named on the drug’s label.
How It Works
Mechanism of action (MoA)- HIV Integrase Inhibitors from dolutegravir
- Organic Cation Transporter 2 Inhibitors from dolutegravir
- Multidrug and Toxin Extrusion Transporter 1 Inhibitors from dolutegravir
- Nucleoside Reverse Transcriptase Inhibitors from abacavir
- Cytochrome P450 1A1 Inhibitors from abacavir
- Nucleoside Reverse Transcriptase Inhibitors from lamivudine
What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.
What It Does in the Body
Physiologic effect (PE)None listed for Abacavir, Dolutegravir, and Lamivudine in the FDA’s index.
From our Patient Information GuideDolutegravir is an integrase strand transfer inhibitor (INSTI). Abacavir and lamivudine are nucleoside analogue reverse transcriptase inhibitors. Together they attack HIV-1 at more than one step. Read How Abacavir, Dolutegravir, and Lamivudine Works
A change it makes in how the body works.
Chemical Family
Chemical structure (CS)None listed for Abacavir, Dolutegravir, and Lamivudine in the FDA’s index.
The chemical family it belongs to, by its structure.
Drug Family
WHO ATC classification- Antivirals for treatment of HIV infections, combinations
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.
Dosage
Triumeq is taken by mouth once daily in adults. You can take it with or without food.
- Get tested for HLA-B*5701 and hepatitis B before starting.
- Children's dosing depends on body weight and uses Triumeq PD tablets for some weights.
- Triumeq and Triumeq PD are not interchangeable milligram for milligram.
Follow your prescriber and the label.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Triumeq tablets once daily
For adults
Dose 600 mg
- One tablet (600 mg abacavir, 50 mg dolutegravir, 300 mg lamivudine) once daily orally with or without food
Good to know
Do not use Triumeq PD in adults
Triumeq PD tablets
These are the doses for children. For adults, see “Triumeq tablets once daily.”
Children 6 kg to under 10 kg Usual dose 3 tablets (60 mg abacavir, 5 mg dolutegravir, 30 mg lamivudine each) once a day
- 3 tablets (60 mg abacavir, 5 mg dolutegravir, 30 mg lamivudine each) once daily: 180 mg ABC, 15 mg DTG, and 90 mg 3TC
Good to know
Triumeq tablets not recommended; disperse in 15 mL drinking water
Children 10 kg to under 14 kg Usual dose 4 tablets (60 mg abacavir, 5 mg dolutegravir, 30 mg lamivudine each) once a day
- 4 tablets (60 mg abacavir, 5 mg dolutegravir, 30 mg lamivudine each) once daily: 240 mg ABC, 20 mg DTG, and 120 mg 3TC
Good to know
Triumeq tablets not recommended; disperse in 20 mL drinking water
Children 14 kg to under 20 kg Usual dose 5 tablets (60 mg abacavir, 5 mg dolutegravir, 30 mg lamivudine each) once a day
- 5 tablets (60 mg abacavir, 5 mg dolutegravir, 30 mg lamivudine each) once daily: 300 mg ABC, 25 mg DTG, and 150 mg 3TC
Good to know
Triumeq tablets not recommended; disperse in 20 mL drinking water
Children 20 kg to under 25 kg Usual dose 6 tablets (60 mg abacavir, 5 mg dolutegravir, 30 mg lamivudine each) once a day
- 6 tablets (60 mg abacavir, 5 mg dolutegravir, 30 mg lamivudine each) once daily: 360 mg ABC, 30 mg DTG, and 180 mg 3TC
Good to know
Triumeq tablets not recommended; disperse in 20 mL drinking water
These are the doses for children. For adults, see “Triumeq tablets once daily.”
HIV-1 infection
For children weighing 25 kg or more
Usual dose 1 tablet (600 mg abacavir, 50 mg dolutegravir, 300 mg lamivudine) once a day
Good to know
Triumeq PD not recommended
Side Effects
The most commonly reported side effects in people taking Triumeq were:
Common side effects
- Trouble sleeping (insomnia)
- Headache
- Tiredness (fatigue)
When to get medical help
- Stop the medicine and get medical help right away if you suspect an allergic reaction to abacavir. Signs include fever, rash, nausea, vomiting, diarrhea, stomach pain, feeling very unwell or achy, cough, shortness of breath, or sore throat.
- Never restart this medicine, or any medicine containing abacavir, after a suspected hypersensitivity reaction. Symptoms can be worse and can lead to death within hours.
- Tell your doctor about yellow skin or eyes, dark urine, or severe stomach pain. These can signal liver problems (hepatotoxicity).
- Tell your doctor if hepatitis B symptoms flare after stopping this medicine, if you have hepatitis B.
- Report symptoms of lactic acidosis (a buildup of acid in the blood) or a severely enlarged, fatty liver. These have been seen with nucleoside analogues and can be fatal.
- Tell your doctor about new symptoms after starting HIV treatment. This may be immune reconstitution syndrome.
- Heart attack (myocardial infarction) is listed among the reported adverse reactions, so seek emergency care for heart attack symptoms.
Warnings and Precautions
- Abacavir hypersensitivity: can be fatal. Stop the medicine at once if you suspect it. Never restart afterward.
- Hepatitis B: test before starting. Severe flares can occur after stopping.
- Liver problems: liver toxicity has been reported with dolutegravir regimens, so monitoring is recommended.
- Lactic acidosis and enlarged fatty liver: reported with nucleoside analogues, including fatal cases.
- Immune reconstitution syndrome: reported with combination HIV treatment.
- Heart attack: listed among reported adverse reactions.
Interactions
Tell your pharmacist about all your medicines. Key ones:
- Dofetilide: contraindicated because levels may rise to dangerous amounts.
- Metformin and dalfampridine: dolutegravir may raise their levels.
- Etravirine: lowers dolutegravir and is not recommended without certain boosting partners.
- Efavirenz: lowers dolutegravir, so extra dolutegravir may be needed.
- Drugs that affect UGT1A1, CYP3A, or P-gp can change dolutegravir levels.
Interactions Listed in the FDA-Approved Label
From the Abacavir, Dolutegravir, and Lamivudine prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
-
Efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, carbamazepine, or rifampinWhat happensThese drugs may decrease dolutegravir concentrations, so the dolutegravir dose in TRIUMEQ is insufficient.What to doIn adults and pediatric patients weighing at least 25 kg, dolutegravir 50 mg twice daily: take an additional TIVICAY 50-mg tablet 12 hours after TRIUMEQ. In patients 6 kg to <25 kg, give an additional weight-based dolutegravir dose 12 hours after TRIUMEQ PD (15 mg, 20 mg, 25 mg or 30 mg by weight band).
-
What happensDecreases dolutegravir concentrations.What to doUse with etravirine without atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir is not recommended.
-
What happensDecreases dolutegravir concentrations.What to doAvoid coadministration because there are insufficient data to make dosing recommendations.
-
Oxcarbazepine, phenytoin, phenobarbital, St. John's wortWhat happensDecrease dolutegravir concentrations.What to doAvoid coadministration because there are insufficient data to make dosing recommendations.
-
What happensIncreases dofetilide concentrations.What to doCoadministration is contraindicated.
-
What happensIncreases dalfampridine levels, which raise the risk of seizures.What to doConsider the potential benefits against the risk of seizures.
-
Cation-containing antacids or laxatives, sucralfate, buffered medications (polyvalent cations, e.g., Mg or Al)What happensDecrease dolutegravir concentrations.What to doAdminister TRIUMEQ or TRIUMEQ PD 2 hours before or 6 hours after these medications.
-
Oral calcium and iron supplements, including multivitamins containing calcium or ironWhat happensDecrease dolutegravir concentrations.What to doWith food, can be taken at the same time. Under fasting conditions, take TRIUMEQ 2 hours before or 6 hours after supplements.
-
What happensIncreases metformin concentrations.What to doRefer to the metformin prescribing information for assessing benefit and risk of concomitant use.
Read the label’s full interactions text
7 DRUG INTERACTIONS Coadministration of TRIUMEQ or TRIUMEQ PD with other drugs can alter the concentration of other drugs and other drugs may alter the concentrations of TRIUMEQ or TRIUMEQ PD. The potential drug-drug interactions must be considered prior to and during therapy. 7.1 Effect of Dolutegravir on the Pharmacokinetics of Other Agents In vitro, dolutegravir inhibited the renal organic cation transporters (OCT)2 (IC 50 = 1.93 microM) and multidrug and toxin extrusion transporter (MATE)1 (IC 50 = 6.34 microM). In vivo, dolutegravir inhibits tubular secretion of creatinine by inhibiting OCT2 and potentially MATE1. Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin). In vitro, dolutegravir inhibited the basolateral renal transporters, organic anion transporter (OAT) 1 (IC 50 = 2.12 microM) and OAT3 (IC 50 = 1.97 microM). However, in vivo, dolutegravir did not alter the plasma concentrations of tenofovir or para-amino hippurate, substrates of OAT1 and OAT3. In vitro, dolutegravir did not inhibit (IC 50 >50 microM) the following: cytochrome P450 (CYP)1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A, uridine diphosphate (UDP)-glucuronosyl transferase (UGT)1A1, UGT2B7, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), bile salt export pump (BSEP), organic anion transporter polypeptide (OATP)1B1, OATP1B3, OCT1, or multidrug resistance protein (MRP)2, or MRP4. In vitro, dolutegravir did not induce CYP1A2, CYP2B6, CYP3A4. Based on these data and the results of drug interaction trials, dolutegravir is not expected to affect the pharmacokinetics of drugs that are substrates of these enzymes or transporters.
Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- Do not use if you carry HLA-B*5701 or have had a prior reaction to abacavir, dolutegravir, or lamivudine.
- Do not use with moderate or severe liver impairment.
- Do not use with dofetilide.
- Get tested for hepatitis B first.
- Tell your doctor about any past use of abacavir-containing medicines.
- Only for children aged at least 3 months and weighing at least 6 kg.
Overdose
There is no known specific treatment for overdose. You would be monitored and given standard supportive care. Dialysis is unlikely to remove much dolutegravir, and it is not known whether it helps with abacavir or lamivudine.
Half-Life and How Your Body Processes It
One Triumeq tablet was bioequivalent to dolutegravir plus an abacavir/lamivudine tablet taken separately. Abacavir is absorbed quickly and has a half-life of about 1.5 hours. Dolutegravir peaks 2 to 3 hours after a dose, reaches steady state in about 5 days, and is mostly cleared through the liver and feces, with some in urine. Triumeq PD gives about 1.7-fold higher dolutegravir than Triumeq, so they are not interchangeable.
Storage
Store and dispense in the original package, protect from moisture, and keep the bottle tightly closed. Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F to 86°F).
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Supplements and Herbs That Interact With Abacavir, Dolutegravir, and Lamivudine
From the licensed clinical database we use, rolled up per supplement, most serious first.56 supplements and herbal products have documented interactions with Abacavir, Dolutegravir, and Lamivudine in the licensed clinical database we use.
Most are manageable, but your pharmacist should know about everything you take, including vitamins and herbals.
- 4Major
- 43Moderate
- 9Minor
- ACTIVATED CHARCOALMajor
- BEERMajor
- SIBERIAN COCKLEBURMajor
- WINEMajor
- ASHWAGANDHAModerate
- BLACK COHOSHModerate
- BOLDOModerate
- BUCHUModerate
Educational information from a licensed clinical database (Natural Medicines). See our data sources and update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Abacavir, Dolutegravir, and Lamivudine: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Abacavir, Dolutegravir, and Lamivudine — the kind of thing our pharmacy team would talk through with you at the counter.
What is this medicine for?
Why did I need blood tests before starting?
How do I take it?
What side effects are common?
What symptoms mean I should stop and call right away?
Can I stop it suddenly if I have hepatitis B too?
Is abacavir, dolutegravir, and lamivudine available over the counter?
When was abacavir, dolutegravir, and lamivudine first available?
What is the brand name of abacavir, dolutegravir, and lamivudine?
What is the generic name of Triumeq?
What drug class is abacavir, dolutegravir, and lamivudine?
What strengths does abacavir, dolutegravir, and lamivudine come in?
How much does abacavir, dolutegravir, and lamivudine cost?
Where can I read the abacavir, dolutegravir, and lamivudine prescribing information (package insert)?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Abacavir, Dolutegravir, and Lamivudine
Skip the scrolling. Ask in your own words and get an answer from Abacavir, Dolutegravir, and Lamivudine’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Abacavir, Dolutegravir, and Lamivudine’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Abacavir, Dolutegravir, and Lamivudine on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, as soon as they can.Abacavir, Dolutegravir, and Lamivudine Forms and Strengths (How It Comes)
Abacavir, Dolutegravir, and Lamivudine comes in 1 dose form, the tablet. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Abacavir, Dolutegravir, and Lamivudine inactive ingredients by manufacturer.
Tablet
How this form is used
- Triumeq treats HIV-1 infection in adults and in children aged at least 3 months and weighing at least 6 kg.
- Triumeq may be taken with or without food.
- Triumeq is taken as one tablet once daily in adults.
- Triumeq tablets and Triumeq PD tablets for oral suspension are not substitutable milligram for milligram.
Abacavir, Dolutegravir, and Lamivudine on the U.S. Market: Products, Makers and Brands
How Abacavir, Dolutegravir, and Lamivudine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
1 company lists 2 Abacavir, Dolutegravir, and Lamivudine product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 2010. Brand names in the directory today include Triumeq and Triumeq PD; the rest are generics.
Also listed with the FDA, not a patient dose form: Unfinished tablet, film coated (1) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.
How Widely Abacavir, Dolutegravir, and Lamivudine Is Used (Medicaid Data)
How many Abacavir, Dolutegravir, and Lamivudine prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is Abacavir, Dolutegravir, and Lamivudine prescribed? Of the 1,682 medications we measure, Abacavir, Dolutegravir, and Lamivudine ranks #641 by Medicaid prescriptions — more than 62% of them.
Utilization by Abacavir, Dolutegravir, and Lamivudine product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
abacavir 600 MG / dolutegravir 50 MG / lamivudine 300 MG Oral Tablet Most dispensed
1 of 1 listed NDCs had Medicaid claims. RxNorm 1546888
abacavir 60 MG / dolutegravir 5 MG / lamivudine 30 MG Tablet for Oral Suspension
1 of 2 listed NDCs had Medicaid claims. RxNorm 2598348
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 2 of the 3 listed Abacavir, Dolutegravir, and Lamivudine NDCs had Medicaid claims.
Compare Abacavir, Dolutegravir, and Lamivudine Products
A representative set of FDA-listed product records for Abacavir, Dolutegravir, and Lamivudine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Tablet | ||||
| ABACAVIR SULFATE 600 mg/1; DOLUTEGRAVIR SODIUM 50 mg/1; LAMIVUDINE 300 mg | Oral | ViiV Healthcare Company | NDA | View NDC → |
| 💊Kits | ||||
| — | — | ViiV Healthcare Company | NDA | View NDC → |
Showing 2 of 2 products — FDA National Drug Code Directory. See every product, package size and price: browse all 2 Abacavir, Dolutegravir, and Lamivudine NDCs →
Abacavir, Dolutegravir, and Lamivudine Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Abacavir, Dolutegravir, and Lamivudine — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Abacavir, Dolutegravir, and Lamivudine in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Abacavir, Dolutegravir, and Lamivudine FDA Approval History
How Abacavir, Dolutegravir, and Lamivudine went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Abacavir, Dolutegravir, and Lamivudine Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Abacavir, Dolutegravir, and Lamivudine recalls since July 2021.
✅No Abacavir, Dolutegravir, and Lamivudine recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Abacavir, Dolutegravir, and Lamivudine in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one exact combination of ingredients (MIN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. A different combination is a different concept with its own page.
- Dose forms
- 2
- Strengths
- 2
- Forms in current FDA listings
- 2 of 2
RxCUI 1546887 -
Dose form (SCDF) Oral TabletIn current FDA listings
RxCUI 1546886Its strength (SCD)-
abacavir 600 mg / dolutegravir 50 mg / lamivudine 300 mg
RxCUI 1546888
-
abacavir 600 mg / dolutegravir 50 mg / lamivudine 300 mg
-
Dose form (SCDF) Tablet for Oral SuspensionIn current FDA listings
RxCUI 2598347Its strength (SCD)-
abacavir 60 mg / dolutegravir 5 mg / lamivudine 30 mg
RxCUI 2598348
-
abacavir 60 mg / dolutegravir 5 mg / lamivudine 30 mg
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Abacavir, Dolutegravir, and Lamivudine Supply and Shortage Status
Whether Abacavir, Dolutegravir, and Lamivudine is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
What Abacavir, Dolutegravir, and Lamivudine Costs Pharmacies (NADAC Benchmark)
What pharmacies pay to buy Abacavir, Dolutegravir, and Lamivudine: the national average from CMS’s weekly NADAC survey, as of Nov 18, 2026. It is the pharmacy’s cost, not your price at the counter.
How the Pharmacy Price Has Changed
Pick a strength to see how its price has changed since Nov 2023.
For brand-name Triumeq, the ABACAVIR SULFATE 600 mg/1; DOLUTEGRAVIR SODIUM 50 mg/1; LAMIVUDINE 300 mg tablet, pharmacies paid an average of $130.09 per tablet as of Nov 18, 2026, up 3.1% from $126.22 a year earlier.
- What pharmacies pay now
- $130.09
- per tablet, as of Nov 18, 2026
- Last 4 weeks
- No change
- from $130.08 on Oct 21, 2026
- Last 12 months
- Up 3.1%
- from $126.22 on Nov 19, 2025
- Lowest and highest since Nov 2023
- $114.51 to $130.13
- per tablet
See the numbers, month by month
| Month | Pharmacy price |
|---|---|
| Nov 2026 | $130.09 |
| Oct 2026 | $130.08 |
| Sep 2026 | $130.01 |
| Aug 2026 | $130.13 |
| Jul 2026 | $130.13 |
| Jun 2026 | $130.11 |
| May 2026 | $130.12 |
| Apr 2026 | $130.01 |
| Mar 2026 | $130.01 |
| Feb 2026 | $130.01 |
| Jan 2026 | $130.01 |
| Dec 2025 | $126.22 |
| Nov 2025 | $126.22 |
| Oct 2025 | $126.33 |
| Sep 2025 | $126.10 |
| Aug 2025 | $126.14 |
| Jul 2025 | $126.10 |
| Jun 2025 | $126.11 |
| May 2025 | $126.01 |
| Apr 2025 | $126.00 |
| Mar 2025 | $126.00 |
| Feb 2025 | $126.00 |
| Jan 2025 | $126.00 |
| Dec 2024 | $121.16 |
| Nov 2024 | $121.14 |
| Oct 2024 | $121.18 |
| Sep 2024 | $121.16 |
| Aug 2024 | $121.16 |
| Jul 2024 | $121.13 |
| Jun 2024 | $121.13 |
| May 2024 | $121.12 |
| Apr 2024 | $121.31 |
| Mar 2024 | $121.31 |
| Feb 2024 | $121.31 |
| Jan 2024 | $121.31 |
| Dec 2023 | $114.51 |
| Nov 2023 | $114.51 |
| Form | Strength | Version | What pharmacies pay | |
|---|---|---|---|---|
| Tablet · Oral | ABACAVIR SULFATE 600 mg/1; DOLUTEGRAVIR SODIUM 50 mg/1; LAMIVUDINE 300 mg | Triumeq (brand) | $130.09 per tablet | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC). Each row spans the package sizes CMS priced; the generic and the brand are priced separately.
Abacavir, Dolutegravir, and Lamivudine Brand Names
Abacavir, Dolutegravir, and Lamivudine has 2 brand names on record: Triumeq and Triumeq PD. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Abacavir, Dolutegravir, and Lamivudine: Manufacturers and Labelers
One company lists Abacavir, Dolutegravir, and Lamivudine products with the FDA. By number of product records, the largest are ViiV Healthcare Company. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Abacavir, Dolutegravir, and Lamivudine Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. ViiV Healthcare Company is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →